ESWL for difficult bile duct stones: a 15-year single centre experience.
OBJECTIVE
To evaluate the efficacy of extracorporeal shock wave lithotripsy (ESWL) for the management of refractory bile duct cholelithiasis in a third level referral centre.


METHODS
The clinical records of all patients treated with a second generation electromagnetic lithotripter (Lithostar Plus, SIEMENS) from October 1990 to April 2005 were evaluated. All patients were monitored during the procedure and antibiotics were administered in case of cholangitis. The chi(2) test and logistic regression analysis were performed as appropriate.


RESULTS
Two hundred and fourteen patients (102 males, 112 females; mean age 74.8 +/- 0.84 years--single stone 97, multiple stones 117) underwent ESWL. The mean number of sessions and shock waves were 3.5 +/- 0.13 and 3477.06 +/- 66.17, respectively. The maximum stone size was 5 cm. Complete stone clearance was achieved in 192 (89.7%) patients. Of the remaining patients 15 required surgery, 2 a palliative stent and in 5 patients stone fragmentation led to effective bile drainage with clinical resolution despite incomplete clearance. Age, sex and stone characteristics were not related to treatment outcome. Major complications occurred in two patients (haemobilia and rectal bleeding) and minor complications in 25 (3 vomiting, 22 arrhythmias). No procedure-related deaths occurred.


CONCLUSIONS
ESWL is a safe and effective technique for clearance of refractory bile duct stones.
Muratori
Rosangela
R
Department of Digestive Diseases and Internal Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. rosangela.muratori@aosp.bo.it
Azzaroli
Francesco
F
Buonfiglioli
Federica
F
Alessandrelli
Flavio
F
Cecinato
Paolo
P
Mazzella
Giuseppe
G
Roda
Enrico
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D042883:Choledocholithiasis / Q000628:therapy*; D005260:Female; D006431:Hemobilia / Q000209:etiology; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008096:Lithotripsy / Q000009:adverse effects; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D016896:Treatment Outcome
Dig Dis Sci. 1992 Jan;37(1):97-100
1728535
Endoscopy. 2003 Aug;35(8):S31-4
12929051
Gut. 1997 Oct;41(4):433-5
9391238
Hepatology. 1992 Feb;15(2):208-14
1735523
Am J Surg. 1993 Apr;165(4):474-8
8480885
Surg Gynecol Obstet. 1983 Jul;157(1):15-9
6857467
Gastrointest Endosc. 1998 May;47(5):327-34
9609422
Gut. 2008 Jul;57(7):1004-21
18321943
Surg Endosc. 2003 Feb;17(2):216-9
12457223
Eur J Gastroenterol Hepatol. 2005 May;17(5):525-7
15827443
Scand J Gastroenterol. 1999 Nov;34(11):1157-61
10582769
Surg Endosc. 2010 May;24(5):1011-6
19851806
Surg Endosc. 1999 May;13(5):452-6
10227940
Gut. 1986 Feb;27(2):196-202
3949248
Gut. 2000 Nov;47(5):728-31
11034593
Am J Surg. 1990 Dec;160(6):610-2; discussion 613
2252122
Gastrointest Endosc. 2001 Jan;53(1):27-32
11154485
Gut. 1998 Dec;43(6):823-9
9824611
Hepatogastroenterology. 1997 Nov-Dec;44(18):1565-8
9427023
J Gastroenterol Hepatol. 2000 Mar;15(3):239-43
10764022
Ital J Gastroenterol Hepatol. 1998 Dec;30(6):624-30
10076787